Another MS Drug Company Joins the Fray

Virogenomics, Inc. announced that it has spun-off Artielle ImmunoTherapeutics, Inc. Artielle is a privately held autoimmune therapeutics company located in Portland. Its technology, licensed from Oregon Health & Science University (OHSU), is based on a new proprietary class of molecules known as Recombinant T cell receptor Ligands (RTLs) that can be tailored to treat a wide range of autoimmune diseases. Artielle has developed a lead compound for the treatment of multiple sclerosis, called RTL1000, which has received Orphan Drug status from the U.S. Food and Drug Administration.